Prior to joining Selecta Biosciences, Inc. in 2010, Dr. Cautreels was Chief Executive Officer of Solvay Pharmaceuticals, the pharmaceuticals division of the Solvay Group, in Brussels, Belgium, from 2005 until Solvay Pharmaceuticals was acquired by Abbott Laboratories in 2010. Before becoming the CEO of Solvay Pharmaceuticals, Dr. Cautreels was its Global Head of R&D.
Prior to joining Solvay, he was with Nycomed‑Amersham and spent 15 years at Sanofi, Sterling‑Winthrop, serving in a variety of R&D management positions in Europe and the United States. Dr. Cautreels is a director of Galapagos NV in Mechelen, Belgium. He also previously held director positions at Seres Therapeutics, Inc., Innogenetics NV and ArQule Inc. Additionally, Dr. Cautreels was previously the President of the Belgian‑Luxemburg Chamber of Commerce for Russia and Belarus. He received his Ph.D. in Chemistry, specializing in Mass Spectrometry, from the University of Antwerp (Antwerp, Belgium), and his financial and business training from the Advanced Management Program at Harvard Business School.
Prior to joining Selecta Biosciences, Inc. in 2008, Dr. Johnston spent nine years at Alkermes, Inc., ascending to the role of Vice President of Operations with responsibility for process development, scale‑up, and clinical manufacturing of pulmonary and sustained-release injectable products, as well as leadership of Alkermes’ manufacturing facility in Chelsea, Massachusetts. He was also a project leader and a member of steering committees at Alkermes for numerous products through various stages of development from Phase 1 through registration.
Dr. Johnston was an original member of Advanced Inhalation Research Inc., or AIR, a private company formed in 1998 and acquired by Alkermes in 1999. Prior to joining AIR, he was a lecturer in the Department of Chemical Engineering at the University of New South Wales in Sydney, Australia. He received his B.Sc. in Chemical Engineering from Queen’s University in Ontario, Canada, and his M.S. and Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology (MIT).
Prior to joining Selecta Biosciences, Inc. in 2011, Dr. Kishimoto was Vice President of Discovery Research at Momenta Pharmaceuticals, Inc., where he served in several leadership positions over the course of five years and led a multidisciplinary research group in advancing both novel and complex generic products for inflammation, oncology, and cardiovascular disease.
Prior to Momenta, he served as Senior Director of Inflammation Research at Millennium Pharmaceuticals, Inc., from 1999 to 2006, where he provided the scientific leadership for four programs in clinical development, and as an Associate Director of Research at Boehringer Ingelheim Pharmaceuticals. Dr. Kishimoto has published over 50 peer‑reviewed articles in scientific journals, including Nature, Science, Cell and The New England Journal of Medicine. Dr. Kishimoto received his B.A. from New College of the University of South Florida and his Ph.D. in Immunology from Harvard University.
Prior to joining Selecta Biosciences, Inc. in 2011, Mr. Abraham was a member of Innovation Legal Group, a boutique intellectual property law firm, and was Executive Director for Patents at Durect Corporation, a specialty pharmaceutical company. He previously served as Senior Patent Counsel for ALZA Corporation (ALZA), a Johnson & Johnson company.
Prior to these roles, Mr. Abraham was employed by the law firms of Wilson Sonsini Goodrich and Rosati, and Finnegan Henderson Farabow Garrett and Dunner. He also was a Patent Examiner at the United States Patent and Trademark Office. Mr. Abraham received his B.S. in Chemical Engineering from the University of Rochester and his J.D. from the George Washington University Law School.
Dr. Sands joined Selecta Biosciences, Inc. in 2015. He previously served as Chief Medical Officer of Targacept, Inc. (now part of Catalyst Biosciences), a biopharmaceutical company, where he was responsible for designing and implementing Targacept’s clinical trials as well as providing strategic and scientific input on intellectual property matters and in‑licensing opportunities. Prior to Targacept, Dr. Sands was the Chief Medical Officer of Plasma Surgical, Inc., a developer of surgical and therapeutic applications, where he was responsible for strategic integrated clinical development plans and execution.
Dr. Sands also previously served as President of Alpha Med Solutions, LLC, a consulting firm. He served in various capacities over the course of eight years at Solvay Pharmaceuticals, which included Executive Vice President, Market Access, Senior Vice President of R&D, acting Chief Medical Officer and Director of Women’s Health. Previously, Dr. Sands served as Senior Regional Medical Director, Professional and Scientific Relations, at Procter & Gamble Pharmaceuticals, was a Founding Partner and Medical Director at Innovation in Medical Education and Training, was a Managing Partner of Women’s Health Care, PC and was Chairman of the OB/GYN Department at Pottstown Memorial Medical Center in Pottstown, Pennsylvania. Dr. Sands received his B.A. in Premedical Sciences from Lehigh University and his M.D. from Hahnemann University School of Medicine.
Dr. Leaman joined Selecta Biosciences, Inc. in October 2017. He previously served as Head of Corporate Development at InfaCare Pharmaceutical Corp., a specialty pharmaceutical company that was recently acquired by Mallinckrodt plc. Prior to this, Dr. Leaman was Chief Financial Officer of Medgenics, Inc., a publicly traded biotech company. He also previously held senior roles at Shire plc and Devon Park Bioventures, a venture capital fund targeting investments in therapeutics companies.
Dr. Leaman brings to Selecta extensive licensing, merger and acquisition experience and began his career serving a range of life sciences companies as an Associate Principal at McKinsey & Company. He received an M.D. from the Perelman School of Medicine at the University of Pennsylvania, an M.B.A. from the Wharton School at the University of Pennsylvania, a B.A. in psychology, philosophy and physiology from Oriel College, University of Oxford while completing a Rhodes Scholarship, and a B.S. in biology from Elizabethtown College.
Before joining Selecta Biosciences, Inc. in October 2017, Mr. Smolinski served as the Vice President and Head of Sanofi/Genzyme’s North American Rheumatology Business Unit, where he led the development of the company’s commercialization plans for the rheumatoid arthritis medicine KEVZARA®. Prior to this, he served as Group Vice President of Immunology & Inflammation, Global Strategic Unit at Sanofi.
Mr. Smolinski also previously held senior commercial roles at Roche-Genentech, Bristol-Myers Squibb, Johnson & Johnson and Savient Pharmaceuticals. He earned a B.S. in health care administration from Oregon State University.
Dr. Ovchinnikov joined Selecta’s Russian operation in 2012. Prior to this, he was a Medical Director for ZAO Sandoz (Russia), a Novartis company, and was responsible for medical support and compliance, clinical trials and pharmacovigilance. Dr. Ovchinnikov was also a member of the Russia Executive Committee at Sandoz and took part in the elaboration of the development strategy for the Russian branch.
Prior to Sandoz, Dr. Ovchinnikov spent four years at Janssen-Cilag, a Johnson & Johnson company, as a Medical Manager for Russia and the Commonwealth of Independent States, and also served as a Clinical Research Associate for PAREXEL RUS LLC, a life sciences consulting firm and a division of PAREXEL International. Dr. Ovchinnikov received his M.S. and Ph.D. in Biochemistry/Oncology/Virology from Lomonosov Moscow State University in Moscow, Russia.